Literature DB >> 9648126

Immunological dysfunction in schizophrenia: a systematic approach.

M Rothermundt1, V Arolt, C Weitzsch, D Eckhoff, H Kirchner.   

Abstract

BACKGROUND: In the present study, immunological alterations were investigated as one possible factor contributing towards the pathogenesis of schizophrenia. Specifically cellular changes, deviating cytokine production and interfering variables were studied in order to improve our understanding of how these factors interact.
METHOD: 44 acutely ill schizophrenics were compared with matched healthy controls. Cell numbers were determined by flow cytometry and cytokine production by whole blood assay and ELISA. A criss-cross technique was employed for the assessment of interfering serum factors.
RESULTS: Cell counts for leukocytes, lymphocytes, pan T cells, activated T cells and the absolute B cell count of the schizophrenic patients were all within normal limits. The absolute and relative monocyte counts, the number of IL-2 receptor carrying T cells and the relative B cell count were slightly elevated. IL-2 and IFN-gamma production were increased while IL-10 production, the sIL-2R and cortisol levels remained unchanged. No interfering serum factors were detected.
CONCLUSION: The deficient production of TH-1 cytokines in schizophrenia is not due either to a changed number of immunocompetent cells or to a counterregulation of the TH-2 cytokine IL-10. Serum factors in in vitro testing are not responsible for the deficient cytokine production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648126     DOI: 10.1159/000026501

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  25 in total

Review 1.  Antineuronal antibodies against neurotransmitter receptors and synaptic proteins in schizophrenia: current knowledge and clinical implications.

Authors:  Johann Steiner; Kolja Schiltz; Hans-Gert Bernstein; Bernhard Bogerts
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

2.  Impaired monocyte activation in schizophrenia: ultrastructural abnormalities and increased IL-1β production.

Authors:  Natalya A Uranova; P D Bonartsev; L V Androsova; V I Rakhmanova; V G Kaleda
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-17       Impact factor: 5.270

Review 3.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 5.  Corticosteroids, immune suppression, and psychosis.

Authors:  Dana C Perantie; E Sherwood Brown
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

6.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

7.  Association study of interleukin 2 (IL2) and IL4 with schizophrenia in a Japanese population.

Authors:  Yuichiro Watanabe; Ayako Nunokawa; Masako Shibuya; Naoshi Kaneko; Hiroyuki Nawa; Toshiyuki Someya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-20       Impact factor: 5.270

8.  Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia.

Authors:  Mark H Rapaport; Catherine Bresee
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 9.  [Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness].

Authors:  A Schuld; D Hinze-Selch; Th Pollmächer
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

Review 10.  Evidence for a dysregulated immune system in the etiology of psychiatric disorders.

Authors:  Sinead M Gibney; Hemmo A Drexhage
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.